December 20, 2016 / 1:21 PM / 7 months ago

BRIEF-Tesaro announces priority review designation for niraparib nda

1 Min Read

Dec 20 (Reuters) - Tesaro Inc

* Tesaro announces priority review designation for Niraparib NDA

* FDA has established a target action date under prescription drug user fee act of June 30, 2017

* An expanded access program (EAP) for Niraparib in United States is planned to open in January 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below